AETHLON MEDICAL INC (AEMD)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-04-21

Key Insights

Director Nicolas Gikakis acquired 21,815 shares of common stock at $2.29 per share on April 17, 2026, increasing his beneficial ownership to 22,844 shares, indicating insider confidence in the company's valuation.
The acquisition was comprised of restricted stock units (RSUs) that vest quarterly over one year (June 30, 2026 through March 31, 2027), suggesting this is a compensation grant rather than open market purchase.
As a director and 10% owner, Gikakis's continued equity compensation demonstrates ongoing commitment to the company, though the vesting schedule is contingent on continued service.

Insider Trading Filed: 2026-04-21

Key Insights

Director Edward G. Broenniman acquired 21,815 shares of common stock at $2.29 per share on April 17, 2026, bringing his total beneficial ownership to 23,454 shares, indicating insider confidence in the company.
The acquisition was executed through Restricted Stock Units (RSUs) that vest quarterly over one year (June 30, 2026 through March 31, 2027), subject to continued service, suggesting a retention-focused compensation structure for company leadership.
As a Director and substantial shareholder, Broenniman's equity stake aligns his interests with other shareholders, though the vesting schedule indicates the company is incentivizing long-term retention rather than immediate value realization.

Insider Trading Filed: 2026-04-21

Key Insights

Director Chetan Shah acquired 21,815 shares of common stock on 04/17/2026 at $2.29 per share through RSU grants, increasing his beneficial ownership to 23,021 shares, indicating confidence in the company's direction.
The RSU grant vests in four equal quarterly installments from June 2026 through March 2027, subject to continued service, which is a standard retention mechanism for executive leadership at the company.
As a Director and 10% owner, Shah's equity compensation demonstrates alignment with shareholder interests, though the modest share price of $2.29 suggests the stock may be trading at depressed levels.

Insider Trading Filed: 2026-04-21

Key Insights

Director Angela Rossetti acquired 21,815 shares of common stock at $2.29 per share on 04/17/2026, increasing her beneficial ownership to 26,207 shares, demonstrating insider confidence in the company's current valuation.
The acquisition was structured as a Restricted Stock Unit (RSU) grant vesting over four equal quarterly installments through March 31, 2027, indicating a retention-focused compensation strategy tied to continued service rather than open market purchase.
As a director and 10% owner, Rossetti's transaction represents a meaningful equity stake that aligns her interests with shareholders, though the grant structure suggests this is compensation-driven rather than a discretionary investment decision.

Current Report Filed: 2026-01-26

Key Insights

Aethlon Medical has amended its Securities Purchase Agreement and Pre-Funded Common Stock Purchase Warrant to remove the requirement of shareholder approval for the exercise of pre-funded warrants, making them immediately exercisable.
The amendments provide the institutional investor with more flexibility and faster access to the pre-funded warrants, which could be seen as a positive development for the company's financing and capital raising abilities.
However, the filing does not provide any additional context or details on the company's overall business performance, financial condition, or future outlook, limiting the insights that can be gleaned from this 8-K filing alone.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.